Drupal.behaviors.print = function(context) {window.print();window.close();}>
As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years'
December 08, 2011
As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years'
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News
Maturing RNAi Industry Suggests It Spends Time in Court and in the Lab
August 25, 2011 / Gene Silencing News
IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Merck, BASF, and More
April 18, 2013 / Gene Silencing News
IP Update: Recent Patents, Patent Applications Awarded to Alcon, Alnylam, Merck, and More
March 21, 2013 / Gene Silencing News
IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Quark, UMass, and More
November 15, 2012 / Gene Silencing News